FGFR2 and cholangiocarcinoma: ,57 In 2020, pemigatinib showed efficacy in patients with previously treated CCA with FGFR2 fusions/rearrangements, with an ORR of 37%, a DCR of 82.4%, a median PFS of 7 months, and a median OS of 17.5 months.9